Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK

Borner, M.; Koeberle, D.; Von Moos, R.; Saletti, P.; Rauch, D.; Hess, V.; Trojan, A.; Helbling, D.; Pestalozzi, B.; Caspar, C.; Ruhstaller, T.; Roth, Arnaud; Kappeler, A.; Dietrich, D; Lanz, D.; Mingrone, W.

doi:10.1093/annonc/mdn058

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Authors		Borner, M. Koeberle, D. Von Moos, R. Saletti, P. Rauch, D. Hess, V. Trojan, A. Helbling, D. Pestalozzi, B. Caspar, C. Ruhstaller, T. Roth, Arnaud Kappeler, A. Dietrich, D Lanz, D. Mingrone, W. show all authors [1 - 16]
Published in		Annals of Oncology. 2008, vol. 19, no. 7, p. 1288-92
Abstract		BACKGROUND: To determine the activity and tolerability of adding cetuximab to the oxaliplatin and capecitabine (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC). PATIENTS AND METHODS: In a multicenter two-arm phase II trial, patients were randomized to receive oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1000 mg/m(2) twice daily on days 1-14 every 3 weeks alone or in combination with standard dose cetuximab. Treatment was limited to a maximum of six cycles. RESULTS: Seventy-four patients with good performance status entered the trial. Objective partial response rates after external review and radiological confirmation were 14% and 41% in the XELOX and in the XELOX + Cetuximab arm, respectively. Stable disease has been observed in 62% and 35% of the patients, with 76% disease control in both arms. Cetuximab led to skin rash in 65% of the patients. The median overall survival was 16.5 months for arm A and 20.5 months for arm B. The median time to progression was 5.8 months for arm A and 7.2 months for arm B. CONCLUSION: Differences in response rates between the treatment arms indicate that cetuximab may improve outcome with XELOX. The correct place of the cetuximab, oxaliplatin and fluoropyrimidine combinations in first-line treatment of MCC has to be assessed in phase III trials.
Keywords		Aged — Aged, 80 and over — Antibodies, Monoclonal/administration & dosage/adverse effects — Antineoplastic Agents/administration & dosage/adverse effects — Antineoplastic Combined Chemotherapy Protocols/therapeutic use — Colorectal Neoplasms/drug therapy/pathology/radiography — Drug Administration Schedule — Exanthema/chemically induced — Female — Follow-Up Studies — Humans — Male — Middle Aged — Neoplasm Metastasis/drug therapy/pathology/radiography — Organoplatinum Compounds/administration & dosage/adverse effects — Switzerland — Time Factors — Treatment Outcome
Identifiers		DOI: 10.1093/annonc/mdn058 PMID: 18349029
Full text		Article (Accepted version) (93 Kb) - Limited access to UNIGE Other version: http://annonc.oxfordjournals.org/cgi/content/full/19/7/1288
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research groups		Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland Groupe Roth Arnaud (oncologie) (285)
Citation (ISO format)		BORNER, M. et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. In: Annals of Oncology, 2008, vol. 19, n° 7, p. 1288-92. doi: 10.1093/annonc/mdn058 https://archive-ouverte.unige.ch/unige:3410